Genmab A/S stock analysis
Genmab A/S (0MGB) Share Price & Analysis
0MGB Stock Chart & Stats
- Day’s Range
- DKK 3,596.00 - DKK 3,702.00
- 52-Week Range
- DKK 1,514.50 - DKK 3,943.00
- Previous Close
- DKK 3,527.00
- Volume
- N/A
- Average Volume (3M)
- 32.76K
- Market Cap
- DKK 214.02B
- Enterprise Value
- DKK 168.19B
- Total Cash (Recent Filing)
- DKK 3.23B
- Total Debt (Recent Filing)
- DKK 143.00M
- Price to Earnings (P/E)
- 45.0
- Beta
- 0.99
- Next Earnings
- Feb 24, 2027 (Est.)
- EPS Estimate
- 15.11
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Genmab A/S News
0MGB FAQ
What was Genmab A/S’s price range in the past 12 months?
What is Genmab A/S’s market cap?
When is Genmab A/S’s upcoming earnings report date?
How were Genmab A/S’s earnings last quarter?
Is Genmab A/S overvalued?
Does Genmab A/S pay dividends?
What is Genmab A/S’s EPS estimate?
How many shares outstanding does Genmab A/S have?
What happened to Genmab A/S’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Genmab A/S?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Genmab A/S
Genmab A/S, a biotechnology firm based in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody-based treatments for various forms of cancer and other serious conditions. The company currently commercializes several key therapeutic antibodies. DARZALEX (daratumumab) is utilized in the treatment of multiple myeloma (MM), specific non-MM blood cancers, and AL amyloidosis. Other marketed offerings include teprotumumab for thyroid eye disease, ofatumumab, which addresses chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic non-small cell lung cancer (NSCLC) as well as gastric or esophageal cancers. Genmab maintains an extensive and active development pipeline, featuring a broad range of experimental therapies. This includes GEN1047, tisotumab vedotin (targeting cervical, ovarian, and other solid cancers), and bispecific antibodies such as DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, which are engineered for solid tumors. Epcoritamab is being developed for relapsed/refractory diffuse large B-cell lymphoma and CLL, while HexaBody-CD38 and DuoHexaBody-CD37 are designed to treat hematological malignancies. Further assets in the pipeline encompass Teclistamab, currently in Phase 2 clinical trials for vaso-occlusive crises, Camidanlumab tesirine for Hodgkin lymphoma and solid tumors, JNJ-64007957 and JNJ-64407564 for MM, PRV-015 for celiac disease, Mim8 for haemophilia A, and Lu AF82422 for multiple system atrophy. Additionally, the company is engaged in approximately 20 pre-clinical research programs. Strategic collaborations are a cornerstone of Genmab's operational model. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of mRNA-based antibody products, with argenx for the discovery of novel therapeutic antibodies in immunology and oncology, and with AbbVie for the development of epcoritamab. Other notable collaborators include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was established in 1999 and is headquartered in Copenhagen, Denmark.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Jan van de Winkel
- Employees
- 3,119
- Website
- www.genmab.com
- Address
- Carl Jacobsens Vej 30, Copenhagen, CD, 2500, DK
Genmab A/S (0MGB) Earnings & Revenues
0MGB Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 5 | 5 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 9 | 0 | 3 |
